Bioventus upgraded by Canaccord Genuity with a new price target
$BVS
Medical/Dental Instruments
Health Care
Canaccord Genuity upgraded Bioventus from Hold to Buy and set a new price target of $7.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $12.00 → $13.00 | Underweight → Neutral | Analyst |
| 12/7/2023 | $7.00 | Hold → Buy | Canaccord Genuity |
| 8/9/2023 | $4.00 → $6.00 | Hold → Buy | Craig Hallum |
| 11/22/2022 | Buy → Hold | Craig Hallum | |
| 11/9/2022 | $18.00 → $6.00 | Buy → Hold | Canaccord Genuity |
| 11/9/2022 | Overweight → Underweight | JP Morgan | |
| 3/15/2022 | $30.00 | Buy | Craig Hallum |
| 3/11/2022 | $20.00 → $18.00 | Overweight | Morgan Stanley |
4 - Bioventus Inc. (0001665988) (Issuer)